Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
Vestal Point Capital
On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities or voting rights. Based on the notification, Vestal Point Capital holds 1,809,843 voting rights, representing 4.84% of the total number of voting rights on May 21, 2025 (37,427,265).
The notification dated May 27, 2025 contains the following information:
A) Voting rights | Previous notification | After the transaction | |||
# of voting rights | # of voting rights | % of voting rights | |||
Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
Ryan Wilder | 0 | 0 | 0 | 0.00% | 0.00% |
Vestal Point Capital, LLC | 0 | 0 | 0 | 0.00% | 0.00% |
Vestal Point Capital, LP | 3,000,688 | 1,809,843 | 0 | 4.84% | 0.00% |
Subtotal | 3,000,688 | 1,809,843 | 4.84% | ||
TOTAL | 1,809,843 | 0 | 4.84% | 0.00% |
Contact:
Nyxoah
John Landry, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.80 |
Daily Change: | 0.09 1.17 |
Daily Volume: | 9,137 |
Market Cap: | US$291.770M |
March 26, 2025 March 13, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load